Literature DB >> 23564700

Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer.

Nilda González-Roibón1, Jeong S Han, Stephen Lee, Zhaoyong Feng, Sehbal Arslankoz, Nathaniel Smith, Philip M Pierorazio, Elizabeth Humphreys, Theodore L Deweese, Alan W Partin, Trinity J Bivalacqua, Misop Han, Bruce Trock, Georges J Netto.   

Abstract

OBJECTIVE: To assess the pathologic characteristics and prognostic significance of periprostatic lymph node (LN) metastasis of prostate cancer. The latter was performed by comparing biochemical recurrence (BCR)-free survival in cases of periprostatic LN metastasis versus matched patients showing pelvic LN metastasis. METHODS AND MATERIALS: We identified 15 patients who underwent radical prostatectomy in our institution (1984-2011) showing positive periprostatic and negative pelvic LN with available follow-up information (group 1). These patients were matched 1:2 to patients with positive pelvic LN (group 2) for pertinent clinicopathologic parameters.
RESULTS: Main locations of positive periprostatic LN were posterior base and mid posterolateral. Overall higher rate of positive margins, smaller LN, and metastasis size were encountered in group 1 compared with group 2. At 5 years postprostatectomy, 69% of patients in group 1 were free of BCR, whereas 26% of those in group 2 remained BCR free, suggesting that patients with periprostatic node metastasis appeared to have a lower risk of BCR. However, the difference was not statistically significant (P = .072). The same was true when adjusted for the effect of prostate-specific antigen, surgical margin status, size of LNs, size of metastasis, age, and year of surgery.
CONCLUSION: Patients with periprostatic node metastasis may have a lower risk of BCR compared with those with metastasis to pelvic LN. Future analysis of larger cohorts will help establish the biologic significance of prostate cancer metastasis to periprostatic LN.

Entities:  

Keywords:  biochemical recurrence; metastasis; periprostatic lymph node; prostate cancer; prostatectomy

Mesh:

Substances:

Year:  2013        PMID: 23564700      PMCID: PMC3978181          DOI: 10.1177/1066896913482729

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  8 in total

1.  Periprostatic lymph node metastasis in prostate cancer and its clinical significance.

Authors:  Fang-Ming Deng; Savvas E Mendrinos; Kasturi Das; Jonathan Melamed
Journal:  Histopathology       Date:  2012-02-28       Impact factor: 5.087

2.  The role of periprostatic and periseminal vesicle lymph node metastasis in the staging and prognosis of prostate cancer.

Authors:  M Kristina Subik; Jorge L Yao; P Anthony di Sant'Agnese; Hiroshi Miyamoto
Journal:  Histopathology       Date:  2012-02-28       Impact factor: 5.087

3.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

4.  Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer.

Authors:  P S Kothari; P T Scardino; M Ohori; M W Kattan; T M Wheeler
Journal:  Am J Surg Pathol       Date:  2001-11       Impact factor: 6.394

Review 5.  Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome.

Authors:  Julia Adams; Liang Cheng
Journal:  Expert Rev Anticancer Ther       Date:  2011-09       Impact factor: 4.512

6.  Analysis of regional lymph nodes in periprostatic fat following robot-assisted radical prostatectomy.

Authors:  Bertram Yuh; Huiqing Wu; Nora Ruel; Timothy Wilson
Journal:  BJU Int       Date:  2011-08-18       Impact factor: 5.588

7.  Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas.

Authors:  Ute Ganswindt; David Schilling; Arndt-Christian Müller; Roland Bares; Peter Bartenstein; Claus Belka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-25       Impact factor: 7.038

8.  Key issues in handling and reporting radical prostatectomy specimens.

Authors:  John R Srigley
Journal:  Arch Pathol Lab Med       Date:  2006-03       Impact factor: 5.534

  8 in total
  1 in total

Review 1.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.